# Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants

> **NCT00961766** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 48 (actual)

## Conditions studied

- Sciatica

## Interventions

- **DRUG:** BG00010 (Neublastin)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00961766
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2014-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00961766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00961766, "Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00961766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*